Injection site rotation: difference between revisions
Diff·revision 14 → 15·00:04, 2 Jul 2025
Difference between revision 14 and revision 15 of Injection site rotation. 6 lines changed; the page grew by 562 bytes.
| Revision 14 — 08:41, 2 Jun 2025 PanelPlannerPam (talk) convert the conversion list to a table so the three syringe scales align 4,064 bytes ±0 | Revision 15 — 00:04, 2 Jul 2025 eGFR_Esme (talk) correct the needle gauge given for subcutaneous administration 4,626 bytes +562 | ||
|---|---|---|---|
| 33 | This article describes practices reported in the clinical literature. It is not medical advice, and research-use compounds are not approved for human administration. | 33 | This article describes practices reported in the clinical literature. It is not medical advice, and research-use compounds are not approved for human administration. |
| 34 | 34 | ||
| + | 35 | == Related considerations == | |
| + | 36 | Needle reuse compounds local trauma, since a needle blunts measurably after a single insertion and a blunted needle produces more tissue damage on the next. See [[Insulin syringe]].{{r|ada2024}} | |
| + | 37 | ||
| + | 38 | Sites with visible or palpable abnormality, scarring, or inflammation are avoided in reported practice, as are areas that will be subject to unusual local blood flow shortly after injection.{{r|usp797}} | |
| + | 39 | ||
| 35 | == References == | 40 | == References == |
| 36 | {{reflist}} | 41 | {{reflist}} |
| ⋮ | ⋮ | ||
| 38 | <ref name="gentile2016">Gentile S, Strollo F, Ceriello A. "Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear?" ''Diabetes Therapy'' 7(3):401–409 (2016). PMID 27503118.</ref> | 43 | <ref name="gentile2016">Gentile S, Strollo F, Ceriello A. "Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear?" ''Diabetes Therapy'' 7(3):401–409 (2016). PMID 27503118.</ref> |
| 39 | <ref name="richter2012">Richter WF, Bhansali SG, Morris ME. "Mechanistic determinants of biotherapeutics absorption following SC administration." ''The AAPS Journal'' 14(3):559–570 (2012). PMID 22619043.</ref> | 44 | <ref name="richter2012">Richter WF, Bhansali SG, Morris ME. "Mechanistic determinants of biotherapeutics absorption following SC administration." ''The AAPS Journal'' 14(3):559–570 (2012). PMID 22619043.</ref> |
| + | 45 | <ref name="usp797">United States Pharmacopeia, General Chapter <797>, ''Pharmaceutical Compounding — Sterile Preparations''.</ref> | |
| 40 | 46 | ||
| 41 | == See also == | 47 | == See also == |